二、该新药的研究情况 证券代码：600196 股票简称：复星医药 编号：临 2024-132 上海复星医药（集团）股份有限公司 关于控股子公司获药品临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海 复宏汉霖生物技术股份有限公司及其控股子公司（以下合称"复宏汉霖"）于近日 收到国家药品监督管理局关于同意 HLX17（即重组抗 PD-1 人源化单克隆抗体注射液， 以下简称"该新药"）用于治疗黑色素瘤、非小细胞肺癌、食管癌、头颈部鳞状细 胞癌、结直肠癌、肝细胞癌、三阴性乳腺癌、微卫星高度不稳定型或错配修复基因 缺陷型肿瘤开展临床试验的批准。复宏汉霖拟于条件具备后于中国境内（不包括港 澳台地区，下同）开展该新药的临床试验。 根据中国相关法规要求，该新药尚需在中国境内开展一系列临床研究并经国家 药品审评部门审批通过后，方可上市。根据研发经验，新药研发存在一定风险，例 如临床试验可能会因为安全性和/或有效性等问题而终止。 新药研发及至上市是 ...

第 1 頁 共 6 頁 v 1.3.0 FF305 確認 不適用 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： | 重新提交 | | --- | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (a joint stock limited company incorporated in the PRC with limited liability) | | | 呈交日期： | 2024年8月30日 | | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | - ...

证券代码：600196 股票简称：复星医药 编号：临 2024-131 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ●本次担保： 1、控股子公司复星医药产业拟为其控股子公司凯茂生物向南京银行申请的 人民币 1,000 万元授信额度项下债务提供最高额连带责任保证担保； 2、本公司、控股子公司宁波复技拟共同为控股子公司淮阴医疗向苏州银行 申请的本金不超过等值人民币 1,000 万元的融资项下债务提供最高额连带责任 保证担保； ●截至 2024 年 8 月 30 日，本集团无逾期担保事项。 ●特别风险提示：截至 2024 年 8 月 30 日，包括本次担保在内，本集团实际 对外担保金额约占 2023 年 12 月 31 日本集团经审计的归属于上市公司股东净资 产的 73.80%，均为本公司与控股子公司/单位之间、控股子公司/单位之间的担 保。敬请投资者注意相关风险。 1 一、概述 （一）本次担保的基本情况 1、2024 年 8 月 ...

证券代码：600196 股票简称：复星医药 编号：临 2024-130 上海复星医药（集团）股份有限公司 关于发起设立之私募股权投资基金进展 ●本次新增认缴不构成《上市公司重大资产重组管理办法》规定的重大资产 重组。 ●本次新增认缴无需提请本公司董事会、股东大会批准。 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●进展情况： 本集团于 2020 年 5 月参与发起设立的苏州基金，截至本公告日期，该基金 累计已获认缴规模为人民币 100,000 万元；其中，本集团合计认缴人民币 33,000 万元，持有该基金 33%的份额。 鉴于资金安排及苏州基金出资进度等方面因素的综合考虑，苏州基金现任 LP 之一的吴中引导基金中心拟将对该基金的认缴出资份额由人民币 8,000 万元 减少至 6,000 万元，由于拟减少认缴份额尚未实缴，苏州基金无需就减少认缴向 吴中引导基金中心支付任何对价；同时，本公司控股子公司宁波复瀛（同为苏州 基金现任 LP 之一）拟将对该基金的认缴出资份额由人民币 32,000 万 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： | 新提交 | | --- | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (a joint stock limited company incorporated in the PRC with limited liability) | | | 呈交日期： | 2024年8月29日 | | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類 ...

证券研究报告 非金融公司|公司点评|复星医药（600196） 制药、器械和医疗服务经营向好 glzqdatemark1 证券研究报告 |报告要点 复星医药发布 2024 年中报，上半年实现收入 204.63 亿元，同比减少 4.36%，实现归母净利 12.25 亿元，同比减少 31.09%，实现扣非归母净利 12.54 亿元，同比减少 8.64%。公司第二季 度实现收入 103.06 亿，同比减少 2.08%，实现扣非归母净利 6.46 亿，同比增长 42.41%。 |分析师及联系人 夏禹 郑薇 SAC：S0590518070004 SAC：S0590521070002 复星医药(600196) 制药、器械和医疗服务经营向好 | --- | --- | |-------------------------|-------------------| | 行 业： | 医药生物/化学制药 | | 投资评级： | 增持（维持） | | 当前价格： | 22.30 元 | | 基本数据 | | | 总股本/流通股本(百万股) | 2,672.40/2,670.43 | | 流通 A 股市值(百万元) | 47,242 ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 20,383,158 thousand, a decrease of 4.37% compared to RMB 21,315,899 thousand for the same period in 2023[5] - Gross profit for the same period was RMB 9,919,772 thousand, down 6.58% from RMB 10,617,379 thousand in 2023[5] - The net profit attributable to shareholders for the six months ended June 30, 2024, was RMB 1,224,799 thousand, a decline of 31.23% from RMB 1,783,642 thousand in 2023[5] - Basic and diluted earnings per share for the current period were RMB 0.46, compared to RMB 0.67 in the previous year, reflecting a decrease of 31.34%[5] - Total comprehensive income for the six months ended June 30, 2024, was RMB 1,662,152 thousand, down 34.24% from RMB 2,527,001 thousand in 2023[7] - Total revenue for the six months ended June 30, 2024, reached RMB 20,383,158,000, with a breakdown of RMB 14,600,938,000 from pharmaceuticals, RMB 2,068,583,000 from medical devices, and RMB 3,657,174,000 from healthcare services[14] - The group reported a net profit of RMB 1,549,732,000 for the six-month period, with a pre-tax profit of RMB 1,931,201,000[14] - The group achieved a net profit attributable to shareholders of RMB 1,225 million, with a net profit of RMB 1,254 million after excluding non-recurring items[43] Research and Development - Research and development expenses decreased to RMB 1,861,736 thousand from RMB 2,134,279 thousand, a reduction of 12.77%[5] - The group’s R&D investment totaled RMB 2,737 million, with R&D expenses amounting to RMB 1,862 million during the reporting period[45] - The company is actively pursuing research and development in immunotherapy, with several new products in the pipeline[71] - The company is committed to research and development, with ongoing efforts to innovate in the fields of oncology and metabolic disorders[122] - The company has reported a robust pipeline of new products, including 50mg Bicalutamide tablets for prostate cancer treatment, indicating a strategic focus on oncology[122] Assets and Liabilities - Cash and bank balances increased to RMB 14,080,459 thousand as of June 30, 2024, compared to RMB 13,693,591 thousand at the end of 2023[8] - Current liabilities rose to RMB 37,401,861 thousand from RMB 33,757,581 thousand, an increase of 10.03%[10] - Non-current liabilities decreased to RMB 19,274,011 thousand from RMB 23,095,761 thousand, a reduction of 16.49%[10] - Total assets less current liabilities amounted to RMB 78,097,577 thousand, down from RMB 79,673,646 thousand in the previous period[10] - The total assets of the group as of June 30, 2024, were RMB 115,499,438,000, with the pharmaceutical division holding assets of RMB 61,412,897,000[14] Market and Product Development - The company has approved a final dividend of RMB 0.27 per ordinary share for the year ending December 31, 2023[30] - The company has received approvals for 9 indications for 4 innovative drugs/biosimilars domestically and internationally during the first half of 2024[41] - The company has 38 generic drug products approved both domestically and internationally, with 24 approved domestically and 14 approved overseas, including 10 ANDAs from Gland Pharma[41] - The company is focusing on expanding its market presence in South America, with its product being the first of its kind approved in that region[71] - The company is exploring potential mergers and acquisitions to bolster its product portfolio and market reach[75] Operational Efficiency - The company reported a significant increase in user data, achieving $1.5 billion in Q3 2023, representing a 25% year-over-year growth[101] - Cost management strategies have led to a 5% reduction in operational expenses, improving overall profitability[101] - The company is committed to sustainability initiatives, with a goal to reduce carbon emissions by 40% by 2025[101] - The company is enhancing its production system to meet international quality standards, with ongoing training and quality risk awareness initiatives[128] - The company is focused on minimizing operational risks associated with mergers and acquisitions, ensuring that synergies are realized post-acquisition[194] Regulatory and Compliance - The company did not adopt any new interpretations that were not yet effective for the reporting period, ensuring consistency in accounting policies[12] - The company is committed to enhancing its quality risk management throughout the product lifecycle and improving operational quality in its healthcare services[192] - The company acknowledges internationalization risks due to geopolitical uncertainties and varying regulatory environments in overseas markets[194] - The company is actively monitoring exchange rate fluctuations as its international operations expand, which could impact asset values and cash flows[196] Sales and Distribution - The pharmaceutical distribution business achieved revenue of RMB 294,727 million, with a net profit of RMB 5,899 million, reflecting a year-on-year decline of 2.07%[146] - The retail pharmacy business generated revenue of RMB 16,558 million, down 6.43% year-on-year, with specialized pharmacies growing over 20%[148] - The company has established a marketing network for medical beauty equipment covering over 100 countries and regions globally[150] - The medical device business has expanded its global marketing network, covering over 100 countries, with direct sales revenue increasing to 86%[136] Future Outlook - The company provided an optimistic revenue guidance for the upcoming quarter, projecting a growth rate of 15%[73] - The company is focusing on expanding its product line to include therapies for additional cancer types[73] - Future projections indicate a strong growth trajectory, with anticipated revenue growth driven by new product launches and market expansion strategies[75] - The company plans to enhance its market presence through strategic acquisitions and partnerships in the next fiscal year[73]

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with total revenue reaching RMB 10 billion, representing a year-on-year growth of 15%[1]. - The company's operating revenue for the first half of 2024 was approximately RMB 20.46 billion, a decrease of 4.36% compared to RMB 21.40 billion in the same period last year[23]. - Net profit attributable to shareholders for the same period was approximately RMB 1.22 billion, down 31.09% from RMB 1.78 billion year-on-year[23]. - The net cash flow from operating activities increased by 5.36% to approximately RMB 1.91 billion, compared to RMB 1.81 billion in the previous year[23][25]. - The company's total assets at the end of the reporting period were approximately RMB 115.54 billion, an increase of 1.82% from RMB 113.47 billion at the end of the previous year[23]. - The basic earnings per share decreased to RMB 0.46, down 31.34% from RMB 0.67 in the same period last year[24]. - The company achieved a revenue of 20.463 billion CNY in the first half of 2024, with a year-on-year growth of approximately 5.31% excluding COVID-related products[54]. - The net profit attributable to shareholders was 1.225 billion CNY, with a net profit of 1.254 billion CNY after excluding non-recurring gains and losses[55]. - The group reported an investment amount of 7.86 billion RMB during the reporting period, a decrease of 54.59% compared to the previous year's investment of 17.31 billion RMB[142]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share within the region by 2025[1]. - The company is focusing on continuous innovation and international expansion, enhancing operational efficiency and integration[34]. - The company aims to strengthen its business focus and improve operational efficiency amid rising costs and competition from multinational enterprises[34]. - The company is focused on expanding its footprint in both domestic and international markets, leveraging its extensive network of subsidiaries and partnerships[12]. - The company is actively involved in the biopharmaceutical sector, with multiple subsidiaries focused on drug development and medical technology[12]. - The company is expanding its market presence through acquisitions and investments in healthcare and pharmaceutical sectors[12]. - The company aims to accelerate international market expansion through strategic layout and external mergers and acquisitions[163]. Research and Development - The company is committed to research and development, focusing on innovative drug solutions and medical technologies[12]. - The group invested a total of 2.737 billion RMB in R&D during the first half of 2024, with R&D expenses amounting to 1.862 billion RMB[56]. - The company has received approval for 9 indications for 4 innovative drugs/biosimilars during the reporting period, with 38 generic drugs approved domestically and internationally[54]. - The company has established a global open innovation R&D system focusing on key therapeutic areas, including solid tumors and blood tumors, and is exploring advanced technologies like RNA and gene therapy[86]. - The company has over 70 innovative drug and biosimilar projects under development as of the end of the reporting period[94]. - The company is focusing on lifecycle management of centralized procurement products while leveraging multi-channel marketing and lean production advantages[105]. Product Development and Launches - New product launches are expected to contribute an additional RMB 1 billion in revenue, with three new drugs set to be introduced by the end of the year[1]. - The company has launched several innovative products, including the first domestically produced PD-1 monoclonal antibody approved in Southeast Asia, with multiple indications[72]. - The company has launched Atomolan, the first oral formulation of glutathione in China, and it is included in the national medical insurance directory[75]. - The company has introduced multiple new pharmaceutical products, including Amlodipine Besylate Tablets for hypertension and Escitalopram Oxalate Tablets for depression, with various packaging options[107]. - The company is focusing on the development of innovative treatments for serious conditions, including Sorafenib Tosylate Tablets for unresectable liver cancer[107]. Financial Health and Investments - The company sold 6.01% of its stake in Gland Pharma for approximately USD 211 million, which increased the net assets by RMB 527 million[26]. - The investment income from long-term equity investments for the first half of 2024 was 841 million RMB, down from 1.02 billion RMB in the same period of 2023[160]. - The company reported a capital reserve increase of 527 million RMB from the partial disposal of its stake in Gland Pharma, which will enhance its net assets[150]. - The fair value of financial assets at the end of the reporting period was 30.63 billion RMB, reflecting a decrease of 3.24 billion RMB due to fair value changes[145]. Regulatory and Compliance - The company is subject to regulatory oversight from various government bodies, including the National Medical Products Administration and the Ministry of Commerce[13]. - The company has received GMP certification for its production lines, ensuring compliance with international quality standards for its products[65]. - The company has been identified as a key environmental regulatory unit, with multiple subsidiaries listed under water, air, and soil pollution categories[185]. - The company has established environmental monitoring systems at wastewater and air emission outlets, ensuring compliance with environmental discharge limits[195]. Environmental Responsibility - The company is actively monitoring and managing its environmental impact through rigorous wastewater treatment protocols[185]. - The company has implemented various wastewater treatment technologies, including anaerobic-aerobic processes and biochemical oxidation[186]. - The company has committed to reducing hazardous waste through third-party processing and has no incidents of illegal dumping or discharge[198]. - The company has established an EHS (Environment, Health, and Safety) special committee and continuously improves EHS-related policies and management strategies[200]. Operational Efficiency - The company is focusing on integrating production and lean operations to enhance competitiveness and operational efficiency in the pharmaceutical business[112]. - The company is building and integrating raw material and formulation production resources to achieve rapid product transformation and create internationally competitive production lines and bases[112]. - The company aims to continuously introduce new products and enhance capacity at the Xuzhou industrial park formulation base[113]. - The company will strengthen its project initiation and early research capabilities to improve R&D efficiency and accelerate the approval of innovative products[170].

证券代码：600196 股票简称：复星医药 编号：临 2024-126 截至2024年6月30日，本次非公开发行募集资金净额已累计使用人民币 400,465.07万元。报告期内（即2024年1月1日至2024年6月30日，下同），本次非 公开发行募集资金实际使用人民币33,327.22万元。截至2024年6月30日，募集资金 余额为人民币45,154.80万元；除经本公司董事会、监事会于2023年7月批准的闲置 募集资金用于暂时补充流动资金尚有人民币44,272.49万元外，募集资金专户余额 为人民币1,294.95万元（包括专户利息收入人民币412.64万元）。 1 二、募集资金管理情况 为规范募集资金管理，保护投资者权益，本公司制订有《上海复星医药（集团） 股份有限公司募集资金管理制度》（以下简称"《募集资金管理制度》"），对募 集资金的存放、使用、项目实施管理及使用情况的监督等方面均作了具体明确的规 定。 本公司及其他作为本次非公开发行募投项目实施主体的控股子公司（以下合称 "募投实施主体"）已分别于相关商业银行（以下合称"专户银行"）开立募集资 金专项账户，且截至 2022 年 7 月 28 日，募投 ...

公司代码：600196 公司简称：复星医药 上海复星医药（集团）股份有限公司 2024 年半年度内部控制评价报告 上海复星医药（集团）股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管 要求（以下简称企业内部控制规范体系），结合上海复星医药（集团）股份有限 公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司截至2024年6月30日（内部控制评价报告基准日） 的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价 其有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事 会建立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运 行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在 任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完 整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告 及相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控 制存在的固有局限性， ...